From the January/February 2022 issue of HealthCare Business News magazine
“For decades, our organizations have benefitted from a strong relationship, dating back to when Dr. Leslie V. Rush Sr. hosted Dr. Alton Ochsner on several occasions in the early 1970s as a guest speaker for special events,” said Dr. Robert Hart, chief medical officer at Ochsner Health, in a statement. “We are thrilled that our relationship has continued to evolve to benefit our patients.”
Oschsner Health recently merged with Lafayette General Health in Louisiana to form Ochsner Lafayette General for patients across the Acadiana (French) region. It included an investment of nearly half a billion dollars from Ochsner over the next 10 years and made it the largest healthcare provider in the Gulf South.
The merger will be completed following regulatory approval and governed by a board made up of Rush community members, physicians and representatives from Ochsner Health.
Rush will continue to use employed and independent physicians, and all medical staff will retain existing privileges. Patients may continue to use existing insurance at all facilities.
Boston Scientific to acquire Baylis Medical for $1.75 billion
Boston Scientific Corporation put up $1.75 billion in October to acquire Baylis Medical Company.
The addition of Baylis Medical adds its radiofrequency NRG and VersaCross Transseptal platforms for left heart access to Boston Scientific’s electrophysiology and structural heart product portfolios. Also included are a family of guidewires, sheaths and dilators.
Traditional use of mechanical needles to pass the septum and access the left side of the heart comes with safety concerns, and individual patient anatomies can make placing the needle correctly challenging. Baylis Medical Company solutions are designed to make crossing the atrial septum safer and more effective for providing treatment during procedures such as atrial fibrillation ablation, left atrial appendage closure and mitral valve interventions.
As a result, Baylis Medical Company has been able to achieve double-digit year-over-year sales growth in each of the last five years, and is expected to rack up net sales of close to $200 million in 2022, according to Boston Scientific. "All of these procedures require physicians to puncture the wall that separates the right atrium from the left atrium — also known as the septum — a procedure that the Baylis Medical technologies can streamline and make safer. As a result, the transseptal access market is expected to grow by double digits in the coming years."
